Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.

British journal of cancer - 1 Dec 1995

Vaz F, Silva M R, Ascensao J L

Abstract excerpt

Roquinimex (Roq) is an immunomodulator known to stimulate cellular immune responses. It is currently used for immunotherapy after bone marrow transplantation (BMT). One of the major features of this compound is an enhancement of natural killer (NK) cell activity and numbers. We studied the in vitro effect of Roq on human peripheral blood NK and adherent lymphokine-activated killer cell (ALAK) activities. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Cell Division
Share to Cells, Cultured

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Killer Cells, Natural

Share to Leukocytes, Mononuclear

Share to Lymphocyte Activation

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 8519666
DOI: 10.1038/bjc.1995.536
PMCID: PMC2034089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.PMID 8519666Read ↗

Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.Semantic proximity Read ↗

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.Semantic proximity Read ↗

Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity.Semantic proximity Read ↗

In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines.Semantic proximity Read ↗

NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.Semantic proximity Read ↗

Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.Semantic proximity Read ↗

Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.Semantic proximity Read ↗

Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.Semantic proximity Read ↗

Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.Semantic proximity Read ↗

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.Semantic proximity Read ↗

Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.